Evidence map›Paper›PMID 32943404›Full record

Trial reportThe European respiratory journal2020

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.

Maryam Edalatifard, Maryam Akhtari, Mohammadreza Salehi, Zohre Naderi, Ahmadreza Jamshidi, Shayan Mostafaei, Seyed Reza Najafizadeh, Elham Farhadi, Nooshin Jalili, Masoud Esfahani and 11 more

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 209 papers, 36 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
209citing papers in PubMed, 36 pooled it
33.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04834375 phase3completednot on this mapstarted 2021, after this paper: background citation

Randomized Open Investigation Determining Steroid Dose (ROIDS-Dose)

TypeinterventionalSponsorNorthwell HealthRan2021 to 2022Enrolled142ConditionsCovid19ArmsWeight-based dexamethasone dose
NCT05047874 unknown statusnot on this mapstarted 2021, after this paper: background citation

Comparison of High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19 - Retrospective Cross-sectional Study

TypeobservationalSponsorBiruni UniversityRan2021 to 2021Enrolled200ConditionsShort-term (3 Days) High-dose (1000 mg) Systemic MethylprednisoloneArmssystemic methylprednisolone
3 · Its place in the literature

Who cites it

209 citing papers in PubMed, 36 syntheses or guidelines pooled it, 430 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Guideline
  18. Pooled it
  19. Pooled it
  20. Use of steroids in COVID-19 patients: A meta-analysis.European journal of pharmacology · 2022
    Pooled it

149 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Maryam EdalatifardAdvanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Maryam AkhtariRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-5342-3440
Mohammadreza SalehiDept of Infectious and Tropical Medicines, Tehran University of Medical Sciences, Tehran, Iran.
Zohre NaderiDept of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-0554-6067
Ahmadreza JamshidiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Shayan MostafaeiDept of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Seyed Reza NajafizadehRheumatology Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1860-9450
Elham FarhadiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Nooshin JaliliDept of Internal Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Masoud EsfahaniDept of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Besharat RahimiAdvanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Hossein KazemzadehAdvanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Maedeh Mahmoodi AliabadiDept of Laboratory, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Tooba GhazanfariImmunoregulation Research Center, Shahed University, Tehran, Iran.
Mohammadreza SattarianSimorgh Clinical Laboratory, Tehran, Iran.
Hourvash Ebrahimi LouyehDept of Rheumatology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Reza RaeeskaramiDept of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran.
Saeidreza JamalimoghadamsiahkaliZiaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Nasim KhajaviradDept of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mahdi MahmoudiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8164-8831
Abdolrahman RostamianRheumatology Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran arostamian@tums.ac.ir.
Tehran University of Medical Sciences · IRImam Khomeini Hospital · IRZero to Three · USIsfahan University of Medical Sciences · IRKermanshah University of Medical Sciences · IRShahed University · IRZanjan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients.

methodsWe conducted a single-blind, randomised controlled clinical trial involving severe hospitalised patients with confirmed COVID-19 at the early pulmonary phase of the illness in Iran. The patients were randomly allocated in a 1:1 ratio by the block randomisation method to receive standard care with methylprednisolone pulse (intravenous injection, 250 mg·day

results68 eligible patients underwent randomisation (34 patients in each group) from April 20, 2020 to June 20, 2020. In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (94.1%

conclusionsOur results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.

Indexed as

COVID-19 Drug TreatmentAdultAgedAnti-Inflammatory AgentsFemaleHospitalizationHumansInjections, IntravenousMaleMethylprednisoloneMiddle AgedPulse Therapy, DrugSeverity of Illness IndexSingle-Blind MethodAnti-Inflammatory AgentsMethylprednisolone

Identifiers

PMID32943404
PMCPMC7758541
OpenAlexW3087214787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.